Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Glutathione vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
Glutathione is distinguished by glutathione is the endogenous tripeptide itself. It is not NAC, GlyNAC, cysteine, glycine, glutamine, or another precursor, and evidence cannot be transferred between them; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Glutathione is distinguished in the current record by glutathione is the endogenous tripeptide itself. It is not NAC, GlyNAC, cysteine, glycine, glutamine, or another precursor, and evidence cannot be transferred between them. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceGlutathione
Glutathione: Mixed route-specific human evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
Glutathione: Not FDA approved. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthGlutathione
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Glutathione
- Glutathione stores and oral bioavailability
- Oxidative-stress and redox biomarkers
- Skin pigmentation and melasma
- Cystic fibrosis
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
GlutathioneNot FDA approved
No FDA-approved glutathione drug product or indication was located. FDA has documented endotoxin-related reactions involving compounded IV glutathione.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
GlutathioneGood biomarkers; mixed outcomes
Controlled oral biomarker and pharmacokinetic trials, a 153-person inhaled cystic-fibrosis RCT, a 58-person oral cystic-fibrosis RCT, a 21-person IV Parkinson pilot, and mixed skin-pigmentation studies.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
GlutathioneNo direct evidence
No controlled direct-glutathione evidence for weight loss, appetite suppression, or body-composition benefit was located.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
GlutathioneNo direct evidence
No controlled direct-glutathione evidence for diabetes treatment or meaningful glycemic benefit was located.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
GlutathioneNo direct evidence
No controlled direct-glutathione evidence for sleep apnea or sleep-quality improvement was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
GlutathioneNo outcomes evidence
No cardiovascular-outcomes benefit is established for direct glutathione. Mechanistic antioxidant rationale and biomarker changes are not outcomes evidence.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
GlutathioneRoute-specific studies only
Oral, topical, inhaled, and IV studies used different condition-specific formulations and protocols. No universal approved dose, route, reconstitution, or storage standard exists.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Which route- and formulation-specific biomarker changes, if any, produce meaningful durable health outcomes and what long-term safety looks like.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
Glutathione
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.